Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
CommuniquÚs de presse de la sociÚtÚ BEIGENE, LTD.
09:29aBeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offeri..
BU
11/24BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatme..
AQ
11/23BEIGENE : Launches Proposed Initial Public Offering on the STAR Market in China - Form 8-K
PU
11/23BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/23BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatme..
BU
11/23BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
BU
11/23BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
BU
11/22BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibit..
BU
11/16BEIGENE : Financial Information - Form 8-K
PU
11/16BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
11/14BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA« (Z..
BU
11/04BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/04BeiGene Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/04BEIGENE, LTD. : Results of Operations and Financial Condition (form 8-K)
AQ
11/04BeiGene Reports Third Quarter 2021 Financial Results
BU
11/04BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63r..
BU
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
PU
10/21BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
BU
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
PU
10/13BEIGENE, LTD. : Termination of a Material Definitive Agreement, Other Events, Financial St..
AQ
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/07BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
BU
09/20BEIGENE : European commercial team is preparing to launch BRUKINSA, the company's first me..
PU
09/20BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/20BEIGENE : Announces Inclusion in FTSE Russell Indices
BU
09/17BEIGENE : Receives Positive CHMP Opinion for BRUKINSA« (Zanubrutinib) for the Treatment of..
BU
09/15BEIGENE : With its second internally developed medicine filed outside China, BeiGene furth..
PU
09/15BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/15BEIGENE : U.S. FDA Grants BRUKINSA« (Zanubrutinib) Accelerated Approval in Relapsed or Ref..
BU
09/13BEIGENE : Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab ..
BU
09/12BEIGENE : to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
BU
09/02BEIGENE : This marks the second FDA approval for BRUKINSA and its third approval in Walden..
PU
09/02BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/01BEIGENE : U.S. FDA Grants BRUKINSA« (Zanubrutinib) Approval in Waldenström's Macroglobulin..
BU
08/26BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/24BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo..
PU
08/24BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/22BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo..
BU
08/19BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA« (Dinutuximab Beta) for ..
PU
08/19BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/18BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for P..
AQ
08/18BEIGENE : Announces Acceptance by Swissmedic of Marketing Authorization Application for BR..
BU
08/17BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA« (Dinutuximab Beta) for ..
BU
08/16BEIGENE : to Host Investor Conference Call and Webcast to Discuss the Company's Early Deve..
BU
08/05BEIGENE : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
08/05BEIGENE, LTD. : Results of Operations and Financial Condition (form 8-K)
AQ
08/05BEIGENE : Reports Second Quarter 2021 Financial Results
BU
08/03BEIGENE : Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton ..
BU
07/30BEIGENE : Announces Approval in Canada of BRUKINSA« (Zanubrutinib) for the Treatment of Pa..
PU
07/30BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/29BEIGENE : Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA..
BU
07/28BEIGENE : Financial Information (Form 8-K)
PU
07/26BEIGENE : Voluntary announcement - update regarding recent business developments
PU
07/26BEIGENE : Announces Approval in Canada of BRUKINSA« (Zanubrutinib) for the Treatment of Pa..
BU
07/21BEIGENE : Regulation FD Disclosure (Form 8-K)
PU
07/21BEIGENE, LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
07/12AMGEN : BeiGene Announces the Approval in China of KYPROLIS (Carfilzomib) for Injection fo..
AQ
07/09BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/09BEIGENE : Announces the Approval in China of KYPROLIS« (Carfilzomib) for Injection for Adu..
BU
07/07BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo..
BU
07/01BEIGENE, LTD. : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
06/30BEIGENE : Financial Information (Form 8-K)
PU
06/28BEIGENE : Material Event (Form 8-K)
PU
06/28BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/24BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/24BEIGENE : China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellula..
AQ
06/24BEIGENE : Tislelizumab is approved for the first-line treatment of advanced non-squamous n..
PU
06/23BEIGENE : China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellula..
BU
06/21BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/21BEIGENE : Announces China NMPA Approval of BRUKINSA for the Treatment of Patients with Rel..
AQ
06/18BEIGENE : Announces China NMPA Approval of BRUKINSA« (Zanubrutinib) for the Treatment of P..
BU
06/17BEIGENE : Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Oci..
PU
06/17BEIGENE, LTD. : Material Modification to Rights of Security Holders, Amendments to Article..
AQ
1  2  3  4  5  6  7Next